FDA Seeks To End Industry’s Use Of Error-Prone Medical Abbreviations
This article was originally published in The Pink Sheet Daily
Executive Summary
In partnership with PhRMA, FDA and the Institute for Safe Medication Practices have launched a campaign to prevent error-prone notation from appearing in labels and advertisements.
You may also be interested in...
Drug Name Mix-Ups Of Aricept/Azilect And Neulasta/Lunesta Under Investigation By FDA
Confusion has occurred with oral and written orders, the Institute for Safe Medication Practices Medication Safety Alert reports.
Drug Name Mix-Ups Of Aricept/Azilect And Neulasta/Lunesta Under Investigation By FDA
Confusion has occurred with oral and written orders, the Institute for Safe Medication Practices Medication Safety Alert reports.
Physician Drug Samples’ Impact On Patient Safety Needs Study, IoM Says
The Institute of Medicine report on medication errors also recommends FDA issue guidances this year on packaging and drug naming.